Abstract: Objective: To investigate the clinical effects of weekly Docetaxel with synchronous radiotherapy in patients with inoperable esophageal cancer. Methods: Eighty-eight patients with esophageal cancer were enrolled into this study over the past three years. The chemotherapeutic regimen included 20 mg of Docetaxel with weekly intravenous drip infusions. Synchronous radiotherapy was conducted. A dose of 60-70 Gy was delivered in 30 to 35 fractions over 6 to 7 weeks. Somerelated drugs were administered during the treatment. Examination using upper digestive tract radiograph, chest CT and upper abdomen supersonic echo-sounder were performed before and after the treatment. The significance of prognostic variables in the survival expectancy was evaluated with Kaplan- Meier survival analysis and the Cox stepwise regression model. Results: Complete response(CR) was found in 29 of 88 cases (33.0%) and partial response (PR) occurred in 36 cases (41.0%),providing an overall response rate (CR+PR) of 74.4%. The 1-, 2-, and 3-year survival rates were 89.8± 3.7% 95% confidence interval (CI), 72.6±7.3% and 38.7±3.6%, respectively. The location of the lesion had no significant effect on the survival (P=0.71). Multivariate analysis showed that the sex, age,location of the lesion and histology were not significant prognostic factors. Conclusion: Weekly docetaxel concurrent with radiotherapy in patients with esophageal cancer is a feasible regimen with tolerable adverse effects.